- Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation
- The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks
- Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”)
Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six million, a figure expected to rise to eight million by 2030 (https://ibn.fm/RYhMD). Earlier this year, one of the leading smoking cessation tools prescribed by physicians, Chantix, was pulled off the market for its cancer risk, leaving a large hole in a fast-growing market rife with opportunity. Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is in a good position to tap into the opportunities offered by this sector, which is expected to reach $63.99 billion by 2026, growing at a CAGR of 16.9% (https://ibn.fm/4ag0A).
Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University (“JHU”) to advance the company’s lead drug candidate MYCO-001 as a smoking cessation treatment. MYCO-001 is 99% pure psilocybin – a hallucinogenic alkaloid, which is often found in mushrooms. Positive clinical data has been…
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF
BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
